ACCELERON PHARMA INC
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $2.8M | $14.0M | $13.5M | $27.8M | $18.1M |
| Operating income | −$51.6M | −$40.8M | −$124.4M | −$110.0M | −$66.1M | −$60.9M |
| Net income | −$50.9M | −$38.1M | −$118.9M | −$108.5M | −$57.0M | −$63.9M |
| Total assets | $932.3M | $504.9M | $314.8M | $389.2M | $247.6M | $146.3M |
| Total liabilities | $77.2M | $55.4M | $22.8M | $24.0M | $22.1M | $37.1M |
| Equity | $855.1M | $449.5M | $292.0M | $365.2M | $225.6M | $109.3M |
| EPS (diluted) | — | — | — | $-0.66 | $0.13 | $-0.45 |
| Shares out. | 53.3M | 51.7M | 45.4M | 38.4M | 37.1M | 32.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −1187.2%
- Net margin
- −1172.6%
- Return on equity
- −6.0%
- Return on assets
- −5.5%
- Return on capital (ROCE)
- −5.9%
- Liabilities / assets
- 8.3%
- Debt / equity
- 0.09×
- Book value / share
- $16.03
- Revenue growth (YoY)
- 56.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- 14.05safe
- Accruals / assets
- 8.5%moderate
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Zakrzewski Joseph SDirector | Nov 19, 2021 | U | 34,499 | — |
| Malik KemalDirector | Nov 19, 2021 | U | 1,622 | — |
| Hite ChristopherDirector | Nov 19, 2021 | U | 930 | — |
| Smith Karen L.Director | Nov 19, 2021 | U | 1,622 | — |
| Mccourt Thomas ADirector | Nov 19, 2021 | U | 6,044 | — |
| Kearney Terrence CDirector | Nov 19, 2021 | U | 6,749 | — |
| Hamill LauraDirector | Nov 19, 2021 | U | 474 | — |
| Nader FrancoisDirector | Nov 19, 2021 | U | 6,749 | — |
| Veness Adam MOfficer — SVP, General Counsel and Sec. | Nov 19, 2021 | U | 23,423 | — |
| Kango SujayOfficer — EVP, Chief Commercial Officer | Nov 19, 2021 | U | 18,509 | — |
| Backstrom Jay T.Officer — EVP, Research and Development | Nov 19, 2021 | U | 21,233 | — |
| Mclaughlin Kevin FOfficer — SVP, CFO and Treasurer | Nov 19, 2021 | U | 10,681 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 22, 2021
- Results of operationsNov 4, 2021
- Results of operationsOct 27, 2021
- Entered a material agreement · Director / officer change · Other material eventSep 30, 2021
- Results of operationsAug 5, 2021
- Results of operationsJul 28, 2021
- Regulation FD disclosureJun 22, 2021
- Shareholder voteJun 21, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BDec 2, 2021
- SC 13D/AACCELERON PHARMA INC.Nov 24, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
- 4OWNERSHIP DOCUMENTNov 22, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.